Furthermore, the inhibition of UCP2, either pharmacologically with Genipin or genetically with siRNAs, was sufficient to reverse the metabolic phenotype and reduce proliferation in PaCa44 and JB6 P+ cancer cell lines [113,136]. Here, UCP2 is linked to cancer.